CX3CL1 and myeloid sarcoma: It was shown that methylprednisolone application in vitro and in vivo increased the chemotaxis of monocytes from MS patients to CCL2, CCL5, and CX3CL1, and this chemotaxis may lead to abnormal levels of CCL5 (Fischer et al., 2019).